Back to Nabota
Nabota
Nabota is a botulinum toxin type A by Daewoong Pharmaceutical, supplied as a 100-unit powder for solution for injection. It is a prescription medicine administered by trained physicians, with visible improvement reported in most patients within about 2 days in the glabellar lines study.
Prescription medicine. Indications, dosing, presentation and storage are taken from the approved Nabota brochure by Daewoong Pharmaceutical; full prescribing information, contraindications and adverse reactions are in the official SPC.
Specifications
- Active substance
- Botulinum toxin type A
- Strength
- 100 Units per vial
- Form
- Powder for solution for injection
- Reconstitution
- Preservative-free 0.9% sodium chloride
- Onset of effect
- About 2 days (glabellar study)
- Glabellar dose
- 20 Units total
- Spasticity dose
- Up to 360 Units per session
- Storage
- 2 to 8 C, do not freeze
- Use within
- 24 hours of reconstitution
- Manufacturer
- Daewoong Pharmaceutical, South Korea
Composition
ACTIVE SUBSTANCE Clostridium botulinum toxin type A, a purified neurotoxin complex. Powder reconstituted with preservative-free 0.9% sodium chloride before intramuscular injection.
Indications
- Moderate to severe glabellar (frown) lines in adults 20 to 65
- Upper limb spasticity after stroke in adults 18 and over
Key features
- Botulinum toxin type A, purified neurotoxin complex
- 100 units per single-use vial, one vial per patient
- Reconstituted with preservative-free 0.9% sodium chloride
- Glabellar lines: 20 Units total per treatment
- Upper limb spasticity: up to 360 Units per session
- Onset of effect by about 2 days in the glabellar study
- Phase 3 trial: non-inferior to a comparator botulinum toxin
- Made by Daewoong Pharmaceutical, South Korea